Protein / target
Parathyroid hormone/parathyroid hormone-related peptide receptor
Protein at a glance
Biological role
G protein-coupled peptide receptor activity
Primary system
Endocrine & metabolic
Strongest disease association
metaphyseal chondrodysplasia, Jansen type
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
5 approved · 1 in clinical development
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
G protein-coupled receptor for parathyroid hormone (PTH) and for parathyroid hormone-related peptide (PTHLH) (PubMed:10913300, PubMed:18375760, PubMed:19674967, PubMed:27160269, PubMed:30975883, PubMed:35932760, PubMed:8397094). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (cAMP) (PubMed:30975883, PubMed:35932760). PTH1R is coupled to G(s) G alpha proteins and mediates activation of adenylate cyclase activity (PubMed:20172855, PubMed:30975883, PubMed:35932760). PTHLH dissociates from PTH1R more rapidly than PTH; as consequence, the cAMP response induced by PTHLH decays faster than the response induced by PTH (PubMed:35932760)
Subcellular location
Domains and Gene Ontology detail (20)Hide
Gene Ontology
- Capical plasma membrane
- Cbasolateral plasma membrane
- Ccytoplasm
- Cnucleus
- Cplasma membrane
- Creceptor complex
- FG protein-coupled peptide receptor activity
- FG protein-coupled receptor activity
- Fparathyroid hormone receptor activity
- Fpeptide hormone binding
- Fprotein homodimerization activity
- Padenylate cyclase-activating G protein-coupled receptor signaling pathway
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
G protein-coupled signalling
- ·G protein-coupled receptor for parathyroid hormone (PTH) and for parathyroid hormone-rel…
- ·G protein-coupled peptide receptor activity
- ·G protein-coupled receptor activity
- ·adenylate cyclase-activating G protein-coupled receptor signaling pathway
View underlying pathways (2)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Parathyroid hormone receptor agonist
Appears in clinical studies involving Hypocalcemia, hypoparathyroidism, postmenopausal osteoporosis, osteoporosis
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 1,304 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 6 total
Hypocalcemia · hypoparathyroidism · postmenopausal osteoporosis
hypoparathyroidism
bone fracture · osteoporosis
osteoporosis · bone fracture · osteogenesis imperfecta
osteoporosis
osteoporosis · postmenopausal osteoporosis · lumbar disk degenerative disorder
Tractability
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (10)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.
- Withdrawn from market
Market withdrawal: Natpar (EMA)
- New publicationRevised European Society of Endocrinology Clinical Practice Guideline: Treatment of Chronic Hypoparathyroidism in Adults.
- New publicationRole of Parathyroid Hormone and Parathyroid Hormone-Related Protein in Protein-Energy Malnutrition.
- Regulatory approval
Approval: Natpar (EMA)
- New publicationPostmenopausal women treated with combination parathyroid hormone (1-84) and ibandronate demonstrate different microstructural changes at the radius vs. tibia: the PTH and Ibandronate Combination Study (PICS).
- New publicationSix months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial.
- New publicationChronic kidney disease mineral and bone disorder in children.
- New publicationTargeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.